Detalhe da pesquisa
1.
Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial.
Clin Infect Dis
; 75(1): e380-e388, 2022 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35219277
2.
UGT1A1 genetic variants are associated with increases in bilirubin levels in rheumatoid arthritis patients treated with sarilumab.
Pharmacogenomics J
; 22(3): 160-165, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35149777
3.
Baseline Severe Acute Respiratory Syndrome Viral Load Is Associated With Coronavirus Disease 2019 Severity and Clinical Outcomes: Post Hoc Analyses of a Phase 2/3 Trial.
J Infect Dis
; 224(11): 1830-1838, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34496013
4.
SON controls cell-cycle progression by coordinated regulation of RNA splicing.
Mol Cell
; 42(2): 185-98, 2011 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-21504830
5.
A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.
Nat Med
; 12(8): 945-9, 2006 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-16892037
6.
Association of complement pathways with COVID-19 severity and outcomes.
Microbes Infect
; 25(4): 105081, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36494054
7.
A therapeutic strategy to target distinct sources of IgE and durably reverse allergy.
Sci Transl Med
; 15(726): eadf9561, 2023 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38091405
8.
Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial.
Nat Med
; 29(10): 2615-2624, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37770652
9.
The Activin/FLRG Pathway Associates with Poor COVID-19 Outcomes in Hospitalized Patients.
Mol Cell Biol
; 42(1): e0046721, 2022 01 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34723652
10.
SERPINB13 is a novel RUNX1 target gene.
Biochem Biophys Res Commun
; 411(1): 115-20, 2011 Jul 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-21723253
11.
Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis.
Proc Natl Acad Sci U S A
; 105(44): 17103-8, 2008 Nov 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-18952841
12.
Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate.
J Clin Pharmacol
; 61(1): 90-104, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32726514
13.
t(8;21)(q22;q22) Fusion proteins preferentially bind to duplicated AML1/RUNX1 DNA-binding sequences to differentially regulate gene expression.
Blood
; 112(4): 1392-401, 2008 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18511808
14.
High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab.
Arthritis Res Ther
; 22(1): 250, 2020 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33081825
15.
Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis.
CPT Pharmacometrics Syst Pharmacol
; 9(7): 405-416, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32453485
16.
Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis.
Arthritis Rheumatol
; 72(9): 1456-1466, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32343882
17.
Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes.
Arthritis Res Ther
; 22(1): 70, 2020 04 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32264972
18.
The hematopoietic transcription factor AML1 (RUNX1) is negatively regulated by the cell cycle protein cyclin D3.
Mol Cell Biol
; 25(23): 10205-19, 2005 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-16287839
19.
Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study.
RMD Open
; 4(1): e000607, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29556418
20.
Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY.
Arthritis Res Ther
; 18(1): 225, 2016 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27716324